alexa
Reach Us +1-218-451-2974

GET THE APP

Hydromethylthionine: Potential Of A Single Drug For Multiple Neurodegenerative Protein Aggregation Disorders | 87400
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Citations : 2245

Journal of Alzheimers Disease & Parkinsonism received 2245 citations as per google scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Hydromethylthionine: Potential of a single drug for multiple neurodegenerative protein aggregation disorders

10th World Congress on Alzheimer's Disease & Dementia

Claude M Wischik

University of Aberdeen, UK

Keynote: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460-C4-044

Abstract
Following our discovery of a fragment from the repeat domain of τ-protein as a structural constituent of the PHF-core in alzheimer’s disease, we developed an assay that captured several key features of the aggregation process. τ-τ u binding through the core τ fragment can be blocked by variants of the Methyl Thioninium (MT) moiety found to dissolve proteolytically stable PHFs isolated from AD brain. The PHF-core tau fragment induces templated proteolytic processing of normal τ, is inherently capable of auto-catalytic self-propagation, can be assembled into characteristic PHFs in vitro and assembly can be blocked by MT-like compounds. The potential utility of these compounds for reduction of pathology and reversal of behavioural deficits was confirmed in tau transgenic mouse models using a stable reduced form of the molecule (hydromethylthionine) which is better absorbed and tolerated. Similar benefits have been shown in a synucein aggregation assay in vitro and in a transgenic synuclein mouse model. These findings led to the first clinical trials to test hydromethylthionine therapy in alzheimer’s disease as a way to block this cascade. Although hydromethylthionine appears to be beneficial as monotherapy, there is a negative interaction with standard symptomatic treatments for AD which was has now been confirmed in a τ transgenic mouse model. In clinical practice, hydromethylthionine therapy will be optimally useful as first-line monotherapy. The efficacy of hydromethylthionine as a synuclein aggregation inhibitor suggests that it may also be useful in parkinson’s disease and dementia of the lewy body type.
Biography

Claude M Wischik has completed his Medical degree at Flinders University in South Australia and PhD at the University of Cambridge, UK. He is the Professor of Psychiatric Geratology at the University of Aberdeen and Chairman of TauRx Therapeutics. He has published extensively on the τ-pathology of AD.
Email:[email protected]
 

Top